Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides caloric support, replenishes glycogen stores, and prevents ketosis by supplying glucose for cellular energy metabolism. Sodium chloride maintains osmotic balance and replaces extracellular fluid and electrolytes.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Fluid and electrolyte replacement,Treatment of dehydration,Intravenous infusion to provide calories and maintain blood glucose levels,Diluent for compatible medications
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; rate and volume determined by patient fluid and electrolyte needs, typically 1-2 L/day in adults.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Exogenous dextrose has a plasma half-life of approximately 15–20 minutes under normal metabolic conditions; in hyperglycemia or insulin resistance, half-life is prolonged.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the Krebs cycle to produce carbon dioxide, water, and energy. Sodium and chloride ions are excreted primarily by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Exogenous dextrose is fully metabolized to carbon dioxide and water; no significant renal or biliary excretion of intact dextrose. Sodium and chloride are primarily excreted renally (greater than 90% of filtered load reabsorbed; excess excreted in urine).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: negligible (<5%) protein binding. Sodium and chloride: not protein bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: distributes into total body water, approximately 0.55–0.6 L/kg (in adults); sodium distributes primarily in extracellular fluid (0.2 L/kg).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% bioavailable. Not administered via oral, intramuscular, or subcutaneous routes for caloric or fluid replacement (oral dextrose has high first-pass metabolism).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific dose adjustment required; monitor fluid and electrolyte balance in renal impairment. In severe renal failure (GFR <15 m L/min), reduce volume to avoid fluid overload.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dose adjustment required; monitor glucose and electrolytes in severe hepatic impairment due to risk of glucose intolerance.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion; dose based on weight and clinical condition. Typical maintenance: 4-8 mg/kg/min dextrose for neonates, 100-150 m L/kg/day for infants, adjusting for fluid and electrolyte needs.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use with caution; reduced renal function may require lower infusion rates and smaller volumes to avoid fluid overload. Monitor serum glucose and electrolytes closely.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA boxed warning.
None.
Risk of hyperglycemia, especially in patients with diabetes mellitus,Monitor serum electrolytes and fluid balance to avoid hypernatremia or fluid overload,Contraindicated in patients with hypertonic dehydration, hypernatremia, or hyperglycemia with ketosis,Use with caution in patients with congestive heart failure, renal failure, or liver cirrhosis,Large volumes may cause electrolyte disturbances or osmotic diuresis
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypertonic dehydration,Hypernatremia,Severe hyperglycemia with ketosis,Known hypersensitivity to dextrose or sodium chloride,Intracranial or intraspinal hemorrhage (if administered via cerebrospinal fluid routes)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, concurrent administration of high-sugar or high-sodium foods may exacerbate hyperglycemia or hypernatremia. Monitor dietary intake of carbohydrates and sodium.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose 5% in 0.2% sodium chloride is a maintenance fluid; no teratogenic risk identified at standard doses. Maternal hyperglycemia from excessive dextrose may cause fetal hyperinsulinism and neonatal hypoglycemia, particularly in third trimester. Hypoosmolar states from improper administration could impair placental perfusion.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Dextrose and sodium chloride are normal components of breast milk; no adverse effects expected at standard infusion rates. M/P ratio not applicable as endogenous substances.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Dose adjustments not typically required. Monitor glucose closely and reduce infusion rate or switch to lower dextrose concentration if hyperglycemia develops. Increased plasma volume in pregnancy may necessitate higher total fluid volumes to maintain euvolemia, but sodium content should be considered to avoid edema.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor serum glucose and electrolytes during prolonged infusion. Administer via large peripheral or central vein to prevent phlebitis. Use with caution in patients with renal impairment, heart failure, or hyperglycemia. Do not administer if solution is discolored or contains particulates. Incompatible with blood products via same line.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Inform your doctor if you have diabetes, heart failure, or kidney problems.,Report any signs of infusion site reactions like pain, redness, or swelling.,This solution contains sugar and salt; do not consume additional salt or sugar without medical advice.,You may need frequent blood tests to monitor your sugar and electrolyte levels.,Do not use this solution at home unless specifically instructed and trained.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides caloric support, replenishes glycogen stores, and prevents ketosis by supplying glucose for cellular energy metabolism. Sodium chloride maintains osmotic balance and replaces extracellular fluid and electrolytes.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by patient fluid and electrolyte needs, typically 1-2 L/day in adults.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% in 0.2% sodium chloride is a maintenance fluid; no teratogenic risk identified at standard doses. Maternal hyperglycemia from excessive dextrose may cause fetal hyperin. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.